Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Liu LX, et al. A monoclonal antibody (LK-4) which differentiates PLA1 from PLA2 platelet extracts but not intact platelets. Thromb. Res. 66: 309-320, 1992. PubMed: 1384161
Liu LX, et al. Development of a monoclonal antibody capable of differentiating platelet PLA1/PLA1, PLA1/PLA2 and PLA2/PLA2 genotypes. Br. J. Haematol. 81: 113-117, 1992. PubMed: 1520609
Liu LX, et al. Heterogenous inhibition of platelet aggregation by monoclonal antibodies binding to multiple sites on GPIIIa. Br. J. Haematol. 91: 976-982, 1995. PubMed: 8547151
Valetin N, et al. Involvement of the cysteine-rich domain of glycoprotein IIIa in the expression of the human platelet alloantigen, PlA1: evidence for heterogeneity in the humoral response. Blood 85: 3028-3033, 1995. PubMed: 7756638
Liu LX, et al. Inhibition of binding of anti-PLA1 antibodies to platelets with monoclonal antibody LK-4. Evidence for multiple PLA1 receptor sites on platelet GPIIIa. Blood 88: 3601-3607, 1996. PubMed: 8896429
